Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 4/20 | 0.47 |
| ▸ | CCNH | P51946 | 4/20 | 0.47 |
| ▸ | EGFR | P00533 | 5/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.45 |
| ▸ | JAK1 | P23458 | 3/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 5/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15648531 | 0.90 | CDK7 (0.44) | CDK7CCNHHDAC1JAK1BRD4 | |
| SCHEMBL15649053 | 0.89 | CDK7 (0.55) | CDK7CCNHEGFRHDAC1JAK1 | |
| SCHEMBL29613463 | 0.89 | CDK7 (0.55) | CDK7CCNHEGFRHDAC1JAK1 | |
| SCHEMBL15648207 | 0.83 | EGFR (0.49) | CDK7CCNHEGFRHDAC1JAK1 | |
| SCHEMBL17141301 | 0.82 | CDK7 (0.52) | CDK7CCNHEGFRHDAC1JAK1 | |
| SCHEMBL17141040 | 0.82 | CDK7 (0.48) | CDK7CCNHEGFRHTR6DRD2 | |
| SCHEMBL29613438 | 0.81 | EGFR (0.51) | CDK7CCNHEGFRHTR6DRD2 | |
| SCHEMBL16665592 | 0.81 | EGFR (0.51) | CDK7CCNHEGFRHTR6DRD2 | |
| SCHEMBL29129122 | 0.80 | CDK7 (0.57) | CDK7CCNHEGFRHDAC1JAK1 | |
| SCHEMBL29613456 | 0.80 | CDK7 (0.57) | CDK7CCNHEGFRHDAC1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787436-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190100511-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-10112927-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| US-20160122323-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-05-05 | — | — | US | disclosed |
| EP-2909194-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Dana-Farber Cancer Institute, Inc. (US) | 2015-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100511-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK9, CDK6 | CDK7 1/4885CCNH 32/4885EGFR 1051/4885 |
| US-20160122323-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK9, CDK6 | CDK7 1/4885CCNH 32/4885EGFR 1051/4885 |
| US-10112927-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK9, CDK6 | CDK7 1/4885CCNH 32/4885EGFR 1051/4885 |
| US-10787436-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK9, CDK6 | CDK7 1/4885CCNH 32/4885EGFR 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.